A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505919-21-00

Acronym

CV029-1001

Enrollment

Registered

2024-04-15

Start date

2024-04-25

Completion date

2025-01-16

Last updated

2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction (HFpEF)

Brief summary

The main trial endpoint is the number of side effects that occur within the study

Detailed description

The secondary trial endpoint is a summary of the amount of MYK-224 in the bloodstream.

Interventions

DRUGPlacebo for bms-986435-01

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The main trial endpoint is the number of side effects that occur within the study	—

Secondary

Measure	Time frame
The secondary trial endpoint is a summary of the amount of MYK-224 in the bloodstream.	—

Countries

Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026